Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00138216 · ClinicalTrials.gov registry record · Phase 1
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
A Phase 1 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00138216 is a Phase 1 study that has completed, run by Children's Oncology Group. The registered enrollment target is 42 participants.
The verdict
NCT00138216, a Phase 1 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as temozolomide, vincristine, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of irinotecan when given together with temozolomide and vincristine in treating young patients with refractory solid tumors.
Interventions
- DRUG temozolomide
- DRUG irinotecan hydrochloride
- DRUG vincristine sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2005-10 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00138216
The ClinicalTrials.gov registry entry for NCT00138216 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which temozolomide is the first listed.
NCT00138216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00138216 about?
NCT00138216 is a clinical study titled "Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors". RATIONALE: Drugs used in chemotherapy, such as temozolomide, vincristine, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE:...
What is the current status of trial NCT00138216?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2005-10. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00138216?
The interventions under investigation include: temozolomide (DRUG), irinotecan hydrochloride (DRUG), vincristine sulfate (DRUG).
Who is sponsoring clinical trial NCT00138216?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.